EMJ Cardiology最新文献

The AZALEA-TIMI 71 Study and the Future of Factor XI Inhibition: Reflections from the American Heart Association Scientific Congress 2023 AZALEA-TIMI 71 研究与因子 XI 抑制的未来：来自美国心脏协会2023年科学大会的思考

EMJ Cardiology Pub Date : 2024-01-25 DOI: 10.33590/emjcardiol/10304347

Karen Lipworth

{"title":"The AZALEA-TIMI 71 Study and the Future of Factor XI Inhibition: Reflections from the American Heart Association Scientific Congress 2023","authors":"Karen Lipworth","doi":"10.33590/emjcardiol/10304347","DOIUrl":"https://doi.org/10.33590/emjcardiol/10304347","url":null,"abstract":"Since its earliest days, the effective use of anticoagulation for prevention of stroke and other thromboembolic events has been limited by the risk and fear of bleeding, which was long believed to be inevitable. However, new understanding of the coagulation cascade suggests that, by targeting factor XI, it may be possible to protect patients from pathological thrombosis without significantly affecting physiological haemostasis, and thus greatly reduce the risk of bleeding. The AZALEA-TIMI 71 trial is the first study to provide definitive evidence that factor XI inhibition substantially reduces bleeding compared to a standard-of-care direct oral anticoagulant (DOAC). Based on an interview with Principal Investigator Christian T. Ruff, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Boston, Massachusetts, USA, this article explains the significance of the AZALEA-TIMI 71 trial results, which showed an unprecedented reduction in the rate of bleeding with abelacimab, an investigational dual-acting factor XI/XIa inhibitor, compared with the DOAC rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.","PeriodicalId":284912,"journal":{"name":"EMJ Cardiology","volume":"15 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139597744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Echocardiography to Diagnose Obstructive Hypertrophic Cardiomyopathy 超声心动图诊断阻塞性肥厚性心肌病的应用

EMJ Cardiology Pub Date : 2023-04-21 DOI: 10.33590/emjcardiol/10308116

Jennifer Taylor

{"title":"Use of Echocardiography to Diagnose Obstructive Hypertrophic Cardiomyopathy","authors":"Jennifer Taylor","doi":"10.33590/emjcardiol/10308116","DOIUrl":"https://doi.org/10.33590/emjcardiol/10308116","url":null,"abstract":"Fabian Knebel, Sana Klinikum, Berlin, Germany, and Department of Cardiology and Angiology, Charité Campus Mitte, Berlin, Germany, opened the podcast with a definition of hypertrophic cardiomyopathy (HCM), which is characterised by left ventricular hypertrophy. Knebel then described the symptoms of the condition, such as shortness of breath and syncope after physical exertion. Up to one in 400 persons carry the genetic mutations that can lead to HCM, which is a dangerous condition if left undiagnosed, potentially leading to ventricular tachyarrhythmias and sudden cardiac death, or end-stage heart failure. HCM is a genetic condition, and genetic testing should be performed in cases of unexplained death so that families can be tested if HCM is diagnosed. Echocardiography is the first imaging method of choice for patients with HCM due to its relatively low cost and wide availability, but cardiac MRI may also be performed to measure left ventricular wall thickness, fibrosis, and left ventricular outflow tract (LVOT) obstruction, and to evaluate the success of therapies such as septal myectomy. When using echocardiography, the first obvious finding to indicate HCM is a thickened left ventricular wall, usually in the interventricular septum. European and American guidelines agree that an end-diastolic left ventricular wall thickness of ≥15 mm should be considered HCM. Knebel provided advice on how to effectively perform echocardiography, including using apical cut planes, and measuring the pressure gradient in the LVOT during the Valsalva manoeuvre. A case study was presented of a patient presenting with signs and symptoms suggestive of myocardial infarction, demonstrating the potential complexity of diagnosing HCM. Knebel concluded with a summary of current therapeutic options, such as septal reduction surgery and septal branch ablation, and pointed out that in the near future there will be medications to reduce LVOT obstruction and alleviate symptoms.","PeriodicalId":284912,"journal":{"name":"EMJ Cardiology","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122092018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interview: Hannah Gower 采访:汉娜·高尔

EMJ Cardiology Pub Date : 2023-03-31 DOI: 10.33590/emjcardiol/10306448

H. Gower

引用次数: 0

Interview: Andrew R.J. Mitchell 采访:Andrew R.J. Mitchell

EMJ Cardiology Pub Date : 2023-03-27 DOI: 10.33590/emjcardiol/10300800

A. Mitchell

引用次数: 0

Hearts are NOT Made to Be Broken: Expert Opinion on Amyloid Light-Chain Cardiac Amyloidosis 心脏不是用来破碎的:淀粉样蛋白轻链心脏淀粉样变性的专家意见

EMJ Cardiology Pub Date : 2023-02-17 DOI: 10.33590/emjcardiol/10309873

G. Palladini

{"title":"Hearts are NOT Made to Be Broken: Expert Opinion on Amyloid Light-Chain Cardiac Amyloidosis","authors":"G. Palladini","doi":"10.33590/emjcardiol/10309873","DOIUrl":"https://doi.org/10.33590/emjcardiol/10309873","url":null,"abstract":"Amyloid light-chain (AL) amyloidosis is a rare systemic disease caused by plasma cell dyscrasia. These plasma cells produce excess Ig light chains, which can misfold, aggregate, and deposit in tissues, resulting in toxicity and organ dysfunction. The heart is among the most commonly affected organs and cardiac involvement is associated with significantly worse outcomes. Despite advances in the treatment of the underlying plasma cell dyscrasia, the survival of patients with advanced heart involvement is extremely poor. The median survival of patients with cardiac AL can be as short as 6 months from diagnosis, depending on severity of cardiac involvement.\u0000It is a condition of high unmet medical need. Timely diagnosis is essential, yet detecting the disease is fraught with challenges, not least a lack of recognition among clinicians. In addition, the treatments that are currently available, which include anti-plasma cell dyscrasia chemotherapy and immunotherapy, are far from ideal, offering complete response rates of around 50% and organ response rates of between 40–50%. However, new antibodies with the potential to target the amyloid deposits have demonstrated encouraging results in early phase studies and are now moving into late-stage development.\u0000Giovanni Palladini, Amyloidosis Research and Treatment Centre Foundation, San Matteo, Italy, and Department of Molecular Medicine, University of Pavia, Italy, explained how these new agents have the potential to change the AL amyloidosis treatment landscape and calls on cardiologists everywhere to consider AL amyloidosis when assessing patients with heart failure (HF).","PeriodicalId":284912,"journal":{"name":"EMJ Cardiology","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125941355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overview of Obstructive Hypertrophic Cardiomyopathy 梗阻性肥厚性心肌病概述

EMJ Cardiology Pub Date : 2022-12-08 DOI: 10.33590/emjcardiol/10168110

A. Pantazis

引用次数: 0

Underdiagnosis and Poor Adherence Are Contributing to Rising Cases of Hypertension 诊断不足和依从性差是导致高血压病例上升的原因

EMJ Cardiology Pub Date : 2022-10-14 DOI: 10.33590/emjcardiol/10186442

Amanda Barrell

引用次数: 0

Cardiac Damage Staging in Patients Undergoing Transcatheter Aortic Valve Replacement: Incremental Value of Global Longitudinal Strain and Right Ventricular-Arterial Coupling 经导管主动脉瓣置换术患者心脏损伤分期:整体纵向应变和右心室-动脉耦合的增量值

EMJ Cardiology Pub Date : 2022-10-06 DOI: 10.33590/emjcardiol/10066961

E. Gutiérrez, I. Carrión, C. Olmos, P. Jiménez, L. Nombela, E. Pozo, P. Mahía, S. Gil, A. de Agustín, F. Islas